The Journal of dermatological treatment · 2013
Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ucak Haydar, Demir Betul, Cicek Demet, Dertlioglu Selma Bakar, Akkurt Zeynep Meltem, Ucmak Derya, Halisdemir Nurhan
Аннотация
BACKGROUND: Pruritus ani (PA) is defined as intense chronic itching affecting perianal skin.
OBJECTIVE: We aimed to determine the efficacy of topical tacrolimus treatment in atopic dermatitis (AD) patients who have PA.
METHODS: The study included 32 patients with AD who were suffering PA. Patients were randomized into two groups. In total, 16 patients used 0.03% tacrolimus ointment and 16 patients used vaseline as placebo. All groups applied topical treatments to their perianal area twice daily for 4 weeks. The treatments were then reversed for 4 weeks after a 2 weeks wash out period.
RESULTS: In total, 32 patients with AD who had refractory anal itching were enrolled in this study. None of the patients had obtained successful results with previous treatments. There was a statistically significant decrease in the recorded EASI, DLQI and itching scores for the tacrolimus group compared to the placebo group at weeks 4 and 6 of treatment (p < 0.05).
CONCLUSION: Topical tacrolimus treatment was well tolerated and effective in controlling persistent PA in AD patients.
OBJECTIVE: We aimed to determine the efficacy of topical tacrolimus treatment in atopic dermatitis (AD) patients who have PA.
METHODS: The study included 32 patients with AD who were suffering PA. Patients were randomized into two groups. In total, 16 patients used 0.03% tacrolimus ointment and 16 patients used vaseline as placebo. All groups applied topical treatments to their perianal area twice daily for 4 weeks. The treatments were then reversed for 4 weeks after a 2 weeks wash out period.
RESULTS: In total, 32 patients with AD who had refractory anal itching were enrolled in this study. None of the patients had obtained successful results with previous treatments. There was a statistically significant decrease in the recorded EASI, DLQI and itching scores for the tacrolimus group compared to the placebo group at weeks 4 and 6 of treatment (p < 0.05).
CONCLUSION: Topical tacrolimus treatment was well tolerated and effective in controlling persistent PA in AD patients.